Apogee Therapeutics Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Affirm

Bristol-Myers

Instacart (Maplebear Inc.)

Confluent

Cargo Therapeutics Inc

Structure Therapeutics Inc

Palo Alto Networks

RayzeBio Inc

Snap

Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.

IPO watch 2024: Which new stocks will hit the market?

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T. / 10:30 a.m. E.T.

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in moderate-to-severe atopic dermatitis in 2024

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Arcellx

CRISPR Therapeutics

Immunome

Nuvalent

Prime Medicine Inc

Vir Biotechnology

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced two abstracts co-written with Apogee's research partner, Paragon Therapeutics, Inc., highlighting the company's lead product candidate, APG777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of AD, have been accepted as e-posters at the upcoming 2023 European Academy of Dermatology and Venereology (EADV) Congress, held October 11-14, 2023, in Berlin, Germany and virtually.

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that members of its management will participate in a fireside chat at the 2023 Stifel Virtual I&I Day on Wednesday, September 20th, 2023 at 9:30 a.m. ET.

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

Lead program, APG777, a novel subcutaneous half-life extended anti-IL-13 antibody, discovered by Paragon, enters first-in-human clinical trial Apogee Therapeutics' recently announced upsized IPO further demonstrates the value of best-in-class antibodies for immunological and inflammatory disorders Mark McKenna, former Chairman, President & CEO of Prometheus Biosciences, joins Apogee as Chairman of the Board of Directors WALTHAM, Mass. , Aug. 29, 2023 /PRNewswire/ -- Paragon Therapeutics, Inc., a biotechnology company dedicated to discovering and developing best-in-class biologics for a range of diseases with high unmet need, today announced the achievement of key milestones by its first spinout company, Apogee Therapeutics (Nasdaq: APGE).

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized and half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis Leadership further strengthened with appointments of industry leaders to its board of directors and executive team SAN FRANCISCO and WALTHAM, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided a review of its pipeline of potentially best-in-class monoclonal antibody (mAb) therapies for I&I diseases, along with key anticipated milestones and recent business progress.

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending positive phase 1 safety and pharmacokinetic data using APG777, the initiation of a 16-week phase 2 study in atopic dermatitis patients is expected in 2024. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031.

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna's knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors' selection decision.

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will participate in the following upcoming investor conferences:

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications (“Apogee” or the “Company”), today announced the closing of its previously announced upsized initial public offering of 20,297,500 shares of common stock, including the full exercise of the underwriters' option to purchase up 2,647,500 additional shares, at a public offering price of $17.00 per share. The aggregate gross proceeds to Apogee from the offering were approximately $345 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. All of the shares were offered by Apogee.

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nabors Energy Transition Corp II

Oddity Tech Ltd

Sagimet Biosciences Inc

Surf Air Mobility Inc

Turbo Energy SA

Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility delayed its direct listing until later this month. In its second IPO attempt, Sagimet Biosciences priced a slightly upsized deal at the midpoint to raise $85 million at a $386 million market cap.

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications (“Apogee” or the “Company”), today announced the pricing of its upsized initial public offering of 17,650,000 shares of common stock at a public offering price of $17.00 per share. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $300 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.   In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Apogee.

Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 and $17 per share, according to a US Securities and Exchange Commission (SEC) filing. The stock offering, which would value the company at as much as $774.5 million, is expected to net Apogee proceeds of between $228.2 million and $263.1 million, depending on whether the underwriters exercise in full their option to purchase additional shares.

Apogee Therapeutics to raise up to $263.1M in IPO

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COPD and asthma. Apogee Therapeutics is still at preclinical stage of development, so the IPO is ultra-high-risk.

IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO

Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments for chronic obstructive pulmonary disease (COPD) looks to raise up to $265.6 million. The company said it is offering 15.625 million shares in the IPO, which is expected to price between $15 and $17 a share.

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

There was one pricing this past week, although it did not meet the criteria for our IPO stats. Two small IPOs and two SPACs submitted initial filings. Two companies are scheduled to begin trading in the week ahead, only one of which is eligible for inclusion in our 2023 stats.

U.S. IPO Weekly Recap: Nano-Cap Debuts In Short And Quiet Holiday Week

Apogee Therapeutics has filed to raise $100 million in a U.S. IPO, although the final figure may differ. The firm is developing drug candidates to treat atopic dermatitis, COPD, and asthma. APGE is still at a very early stage of development, so the IPO would be high-risk.

Apogee Therapeutics Begins $100 Million IPO Rollout

News for Apogee Therapeutics Inc Stock (APGE)